Recurrent respiratory papillomatosis: Update 2008

Current Opinion in Otolaryngology and Head and Neck Surgery

Volumn 16, Issue 6, 2008, Pages 536-542

  Gallagher, Thomas Q ^a   Derkay, Craig S ^b,c  

^a Naval Medical Center   (United States)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^c Childrens Hospital of the Kings Daughters   (United States)

Author keywords

Cidofovir; Human papilloma virus; Human papilloma virus vaccine; Pulsed dye laser; Recurrent respiratory papillomatosis

Indexed keywords

CELECOXIB; CIDOFOVIR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; L1 VIRUS LIKE VACCINE; PLACEBO; UNCLASSIFIED DRUG; VIRUS VACCINE; WART VIRUS VACCINE;

ADJUVANT THERAPY; CARBON DIOXIDE LASER; CLINICAL TRIAL; DEBRIDEMENT; DISEASE SEVERITY; DRUG EFFICACY; HEAD AND NECK CANCER; HERD IMMUNITY; HOST RESISTANCE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNE SYSTEM; LARYNX PAPILLOMATOSIS; LASER; LASER SURGERY; LOW DRUG DOSE; MALIGNANT TRANSFORMATION; MOLECULAR BIOLOGY; PATHOGENESIS; POTASSIUM TITANYLPHOSPHATE LASER; PREVALENCE; PRIORITY JOURNAL; PULSED DYE LASER; RECURRENT RESPIRATORY PAPILLOMATOSIS; RETINITIS; REVIEW; SOCIAL STATUS; UNITED STATES; UTERINE CERVIX CANCER; VACCINATION; ALPHAPAPILLOMAVIRUS; ARTICLE; CHILD; LARYNX TUMOR; PAPILLOMA; RECURRENT DISEASE; RESPIRATORY TRACT TUMOR; VIROLOGY;

ALPHAPAPILLOMAVIRUS; CHILD; HUMANS; LARYNGEAL NEOPLASMS; PAPILLOMA; PAPILLOMAVIRUS VACCINES; RECURRENCE; RESPIRATORY TRACT NEOPLASMS;

EID: 60249102888     PISSN: 10689508     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOO.0b013e328316930e     Document Type: Review

References (59)

1. Hobbs CG, Birchall MA. Human papillomavirus infection in the etiology of laryngeal carcinoma. Curr Opin Otolaryngol Head Neck Surg 2004; 12:88-92.
2. Leung R, Hawkes M, Campisi P. Severity of juvenile onset recurrent respiratory papillomatosis is not associated with socioeconomic status in a setting of universal healthcare. Int J Pediatr Otorhinolaryngol 2007; 71:965-972.
3. Wiatrak BJ. Overview of recurrent respiratory papillomatosis. Curr Opin Otolaryngol Head Neck Surg 2003; 11:433-441.
4. Wiatrak BJ, Wiatrak DW, Broker TR, Lewis L. Recurrent respiratory papillomatosis: a longitudinal study comparing severity associated with human papilloma viral types 6 and 11 and other risk factors in a large pediatric population. Laryngoscope 2004; 114 (Suppl 104):1-23.
5. Derkay C, Darrow D. Recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol 2006; 115:1 -11.
6. Shykhon M, Kuo M, Pearman K. Recurrent respiratory papillomatosis. Clin Otolaryngol Allied Sci 2002; 27:237-243.
7. Derkay CS. Task force on recurrent respiratory papillomas: a preliminary report. Arch Otolaryngol Head Neck Surg 1995; 121:1386-1391.
8. Reeves WC, Ruparelia SS, Swanson KI, et al. National registry for juvenile-onset respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 2003; 129:976-982.
9. Weller SC, Stanberry LR. Estimating the population of HPV. JAMA 2007; 297:876-878.
10. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States. JAMA 2007; 297:813-819.
11. FUTURE II Study Group. Quadrivalent vaccine against HPV to prevent high-grade cervical lesions. N Engl J Med 2007; 356:1915-1927.
12. Villa LL, Costa RL, PettaCA, et al. Prophylactic quadrivalent HPV (types 6,11, 16 and 18) L1 virus-like particle vaccine in young women: a randomized double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6:271 -278.
13. Markowitz LE, Dunne EF, Saraiya M, et al. Quadrivalent HPV: recommenda- tionsof theACIP. MMWRRecomm Rep 2007; 56:1-24. http://www.cdc.gov/ nip/vaccine/hpv. [Acessed 23 March 2007].
14. Committee on Infectious Diseases. Prevention of HPV infection: provisional recommendations for immunization of girls and women with quadrivalent HPV vaccine. Pediatrics 2007; 1735:666-668.
15. Reisinger KS, Block SL, Lazcano-Ponce E, et al. Safety and persistent immunogenicity of a quadrivalent HPV types 6,11,16 18 L1 virus-like particle vaccine in preadolescents and adolescents. Pediatr Infect Dis J 2007; 26:201 -209.
16. May J. HPV vaccination - a paradigm shift in public health. Aust Fam Physician 2007; 36:106-111.
17. Giuliano AR. Human papillomavirus vaccination in males. Gynecol Oncol 2007; 107:S24-S26.
18. Colgrove J. The ethics and politics of compulsory HPV vaccination. N Engl J Med 2006; 355:2389-2391.
19. Block SL, Nolan T, Sattler C, et al. Comparison of the immunogenicity and reactogenecity of a prophylactic quadrivalent human papillomavirus (types 6, 11,16 and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006; 118:2135-2145.
20. Charo RA. Politics, parents and prophylaxis-mandating HPV vaccination in the US. N Engl J Med 2007; 356:1905-1908.
21. Zimmerman RK. Ethical analysis of HPV vaccine policy options. Vaccine 2006; 24:4812-4820.
22. Dallard C. Legislating against arousal: the growing divide between federal policy and teenage sexual behaviour. Gutmacher Policy Rev 2006; 9:12-16.
23. Bleakley A, Hennessy M, Fishbein M. Public opinion on sex education in US schools. Arch Pediatr Adolesc Med 2006; 160:1151-1156.
24. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papilloma vaccination strategies. Emerg Infect Dis 2007; 13:28-41.
25. Tissot AM, Zimet GD, Rosenthal SL, et al. Effective strategies for HPV vaccine delivery: the views of pediatricians. J Adolesc Health 2007; 41:119-125.
26. Kahn JA, Rosenthal SL, Tissot AM, et al. Factors influencing pediatricians' intentions to recommend human papillomavirus vaccines. Ambul Pediatr 2007; 7:367-373.
27. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like particle vaccine against infection with HPV types 16 and 18 in young women: an interim analysis of a phase II double-blind, randomized controlled trial. Lancet 2007; 369:2161 -2170.
28. Pederson C, Petaja T, Strauss G, et al. Immunization of early adolescent females with HPV type 16 and 18 L1 virus-like particle vaccine containing ASO4 adjuvant. J Adolesc Health 2007; 40:564-571.
29. Freed GL, Derkay CS. Prevention of RRP: the role of HPV vaccination. Int J Pediatr Otorhinolaryngol 2007; 70:1799-1803.
30. Hildesheim A, Herrero R, WasholderS, et al. Effect of HPV 16/18 L1 virus-like particle vaccine among young women with preexisting infection. JAMA 2007; 298:743-753.
31. Markowitz L. HPV vaccines - prophylactic, not therapeutic. JAMA 2007; 298:805-806.
32. Monie A, Hung CF, Wu T-C. Preventive and therapeutic HPV vaccines. Curr Opin Invest Drugs 2007; 8:1038-1050.
33. Badaracco G, Venuti A. HPV therapeutic vaccines in head and neck tumors. Expert Rev Anticancer Ther 2007; 7:753-766.
34. D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007; 356:1944-1956.
35. Syrjanen S. HPV in head and neck cancer. J Clin Virol 2005; 32 (Suppl 1): S59-S66.
36. Kawana K, Yasugi T, Yoshikawa H, et al. Evidence for the presence of neutralizing antibodies against HPV type6 in infants born to mothers with condylomata. Am J Perinatol 2003; 20:11 -16.
37. Schaffer A, Brotherton J, Booy R. Do HPV vaccines have any role in newborns and the prevention of RRP in children? J Paediatr Child Health 2007; 43:579-580.
38. Stern Y, Felipovich A, Cotton R, Segal K. Immunocompetency in children with recurrent respiratory papillomatosis: prospective study. Ann Otol Rhinol Laryngol 2007; 116:169-171.
39. 2 laser removal of recurrent respiratory papillomatosis: a prospective analysis. Laryngoscope 2003; 113:139-143.
40. Myer CM III, Willging JP, McMurray S, Cotton RT. Use of a laryngeal microresector system. Laryngoscope 1999; 109:1165-1166.
41. El Bitar MA, Zalzal GH. Powered instrumentation in the treatment of recurrent repiratory papillomatosis: an alternative to the carbon dioxide laser. Arch Otolaryngol Head Neck Surg 2002; 128:425-428.
42. Patel N, Rowe M, Tunkel D. Treatment of recurrent respiratory papillomatosis in children with the microdebrider. Ann Otol Rhinol Laryngol 2003; 112: 7-10.
43. Burns JA, Zeitels SM, Akst LM, et al. 532 nm pulsed potassium-titanylphosphate laser treatment of laryngeal papillomatosis under general anesthesia. Laryngoscope 2007; 117:1500-1504.
44. Hartnick CJ, Boseley ME, Franco RA, et al. Efficacy of treating children with anterior commissure and true vocal fold respiratory papilloma with the 585-nm pulsed-dye-laser. Arch Otolaryngol Head Neck Surg 2007; 133:127-130.
45. Koufman JA, Rees CJ, Frazier WD, et al. Office-based laryngeal laser surgery: a review of 443 cases using three wavelengths. Otolaryngol Head Neck Surg 2007; 137:146-151.
46. Mouadeb DA, Belafsky PC. In-office laryngeal surgery with the 585 nm pulsed dye laser (PDL). Otolaryngol Head Neck Surg 2007; 137:477-481.
47. Rees CJ, Halum SL, Wijewickrama RC, et al. Patient tolerance of in-office pulsed dye laser treatments to the upper aerodigestive tract. Otolaryngol Head Neck Surg 2006; 134:1023-1027.
48. Rees CJ, Postma GN, Koufman JA. Cost savings of unsedated office-based laser surgery for laryngeal papillomas. Ann Otol Rhinol Laryngol 2007;116:45-48.
49. Ivey CM, Woo P, Altman KW, Shapshay SM. Office pulsed dye laser treatment for benign laryngeal vascular polyps: a preliminary study. Ann Otol Rhinol Laryngol 2008; 117:353-358.
50. Schraff S, Derkay CS. Survey of ASPO membership regarding management of RRP distal spread and the use of adjuvant therapies. Arch Otolaryngol Head Neck Surg 2004; 130:1039-1042.
51. Pransky SM, Albright JT, Magit AE. Long-term follow-up of pediatric recurrent respiratory papillomatosis managed with intralesional cidofovir. Laryngoscope 2003; 113:1583-1587.
52. Mandell DL, Arjman EM, Kay DJ, et al. Intralesional cidofovir for pediatric recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 2004; 130:131 9-1323.
53. Co J, Woo P. Office based intralesional injection of cidofovir in adult-onset RRP. Ann Otol Rhinol Laryngol 2004; 113:859-862.
54. Donne AJ, Hampson L, Rothera MP, et al. Effects of cidofovir on a novel cell-based test system for recurrent respiratory papillomatosis. Head Neck 2007; 29:741 -750.
55. Chadha NK, James AL. Antiviral agents for the treatment of recurrent respiratory papillomatosis: a systematic review of the English-language literature. Otolaryngol Head Neck Surg 2007; 136:863-869.
56. McMurray JS, Conner N, Ford C. Cidofovir efficacy in RRP: a prospective blinded placebo-controlled study. Ann Otol Rhinol Laryngol 2008; 117:477-483.
57. Derkay CS. Cidofovir for recurrent respiratory papillomatosis (RRP): a reassessment of risks. Int J Pediatr Otorhinolaryngol 2005; 69:1465-1467.
58. Lindsay F, Bloom D, Pransky S, et al. Histologic review of cidofovir-treated recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol 2008; 117:11 -117.
59. Wu R, Coniglio SJ, Chan A, et al. Up-regulation of Rac 1 by epidermal growth factor mediates COX-2 expression in recurrent respiratory papillomas. Mol Med 2007; 13:143-150.